An interesting trial of T3 therapy for COVID-19 patients is being set up trialsjournal.biomedcentral... .
The trial uses large doses of T3. Although not as large as described in the trial summary. References to e.g. '0.8g/kg i.v' should refer to mcg!
The 'Full study protocol' document gives a better description on page 35. (I'm not going to read this 68 page document).
'For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105μg of T3)that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.'
So, patients will typically receive a 60 mcg bolus L-T3 followed by 210 mcg daily for 3 days and 105 mcg thereafter.
THIS IS NOT AN INDEPENDENT STUDY.
'The Thy-Support trial will be entirely financially supported by Uni-Pharma S.A. (Greece) including materials used in this study. Uni-Pharma S.A. will have full oversight of the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. The sponsor will also fund the CRO (PHARMASSIST) which will undertake collection, analysis, and interpretation of data in collaboration with a Data Monitoring Committee.'
We should expect bias in favour of L-T3 but it will be interesting to see the results.